Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study.
multiple myeloma
next-generation sequencing
personalized molecular therapies
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Feb 2023
28 Feb 2023
Historique:
received:
03
12
2022
revised:
18
02
2023
accepted:
23
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
Despite that cytogenetic and molecular analysis of tumor cells can rapidly identify recurring molecular abnormalities, no personalized therapy is currently available in the setting of relapsed/refractory multiple myeloma (r/r MM). MM-EP1 is a retrospective study aimed at comparing a personalized molecular-oriented (MO) versus a non-molecular-oriented (no-MO) approach in r/r MM. Actionable molecular targets and their associated therapies were the BRAF V600E mutation and BRAF inhibitors; t(11;14)(q13;q32) and BCL2 inhibitors; and t(4;14)(p16;q32) with FGFR3 fusion/rearrangements and FGFR3 inhibitors. One hundred three highly pretreated r/r MM patients with a median age of 67 years (range 44-85) were included. Seventeen (17%) patients were treated using an MO approach with BRAF inhibitors (vemurafenib or dabrafenib, Despite the low number of patients treated with an MO approach, this study highlights the strengths and weakness of a molecular-targeted approach for the treatment of multiple myeloma. Widespread biomolecular techniques and improvement of precision medicine treatment algorithms could improve selection for precision medicine in myeloma.
Sections du résumé
BACKGROUND
BACKGROUND
Despite that cytogenetic and molecular analysis of tumor cells can rapidly identify recurring molecular abnormalities, no personalized therapy is currently available in the setting of relapsed/refractory multiple myeloma (r/r MM).
METHODS
METHODS
MM-EP1 is a retrospective study aimed at comparing a personalized molecular-oriented (MO) versus a non-molecular-oriented (no-MO) approach in r/r MM. Actionable molecular targets and their associated therapies were the BRAF V600E mutation and BRAF inhibitors; t(11;14)(q13;q32) and BCL2 inhibitors; and t(4;14)(p16;q32) with FGFR3 fusion/rearrangements and FGFR3 inhibitors.
RESULTS
RESULTS
One hundred three highly pretreated r/r MM patients with a median age of 67 years (range 44-85) were included. Seventeen (17%) patients were treated using an MO approach with BRAF inhibitors (vemurafenib or dabrafenib,
CONCLUSION
CONCLUSIONS
Despite the low number of patients treated with an MO approach, this study highlights the strengths and weakness of a molecular-targeted approach for the treatment of multiple myeloma. Widespread biomolecular techniques and improvement of precision medicine treatment algorithms could improve selection for precision medicine in myeloma.
Identifiants
pubmed: 36900299
pii: cancers15051508
doi: 10.3390/cancers15051508
pmc: PMC10001403
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Institut Gustave Roussy
ID : 0
Références
Cell Death Dis. 2015 Jan 15;6:e1590
pubmed: 25590800
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):397-405
pubmed: 31036508
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Front Oncol. 2019 Oct 24;9:1137
pubmed: 31709194
Blood. 2017 Nov 30;130(22):2401-2409
pubmed: 29018077
Nature. 2013 Sep 19;501(7467):338-45
pubmed: 24048066
Ann Oncol. 2014 Jan;25(1):126-31
pubmed: 24285021
Haematologica. 2020 Jul 23;105(10):2358-2367
pubmed: 33054076
Oncogene. 2001 Jun 14;20(27):3553-62
pubmed: 11429702
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
EJHaem. 2020 Aug 06;1(1):318-322
pubmed: 35847743
Blood Adv. 2021 Aug 10;5(15):3016-3020
pubmed: 34351389
Cancer Discov. 2021 Apr;11(4):900-915
pubmed: 33811123
Am Soc Clin Oncol Educ Book. 2016;35:e442-8
pubmed: 27249752
Clin Cancer Res. 2014 Feb 15;20(4):804-13
pubmed: 24270684
Front Oncol. 2020 Feb 25;10:189
pubmed: 32181154
Oncotarget. 2015 Sep 15;6(27):24205-17
pubmed: 26090869
Front Pharmacol. 2021 Mar 15;12:628690
pubmed: 33790792
JCO Precis Oncol. 2018 Aug 31;2:
pubmed: 32913989
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
BMJ Case Rep. 2022 Apr 8;15(4):
pubmed: 35396243
Ann Oncol. 2018 Sep 1;29(9):1895-1902
pubmed: 30137196
Clin Cancer Res. 2021 Dec 1;27(23):6432-6444
pubmed: 34518309
Lancet Oncol. 2015 Dec;16(16):e581-2
pubmed: 26678200
J Clin Oncol. 2010 Jan 1;28(1):92-8
pubmed: 19933921
J Clin Oncol. 2020 Nov 20;38(33):3895-3904
pubmed: 32758030
Cancers (Basel). 2021 Jun 13;13(12):
pubmed: 34199304
Clin Cancer Res. 2016 Aug 15;22(16):4039-44
pubmed: 26847058
Cancer Discov. 2013 Aug;3(8):862-9
pubmed: 23612012
Blood. 2019 Jan 10;133(2):156-167
pubmed: 30455381
Lancet Oncol. 2020 Dec;21(12):1630-1642
pubmed: 33129376
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Blood. 2011 Jan 6;117(1):211-20
pubmed: 20974671
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113
pubmed: 27531699
Front Oncol. 2022 Jan 20;11:819127
pubmed: 35127532
Blood. 2019 Feb 14;133(7):660-675
pubmed: 30587529